Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Preclinical evaluation of degradation kinetics and elemental mapping of first- and second-generation bioresorbable magnesium scaffolds.

Joner M, Ruppelt P, Zumstein P, Lapointe-Corriveau C, Leclerc G, Bulin A, Castellanos MI, Wittchow E, Haude M, Waksman R.

EuroIntervention. 2018 Oct 12;14(9):e1040-e1048. doi: 10.4244/EIJ-D-17-00708.

2.

Second-generation magnesium scaffold Magmaris: device design and preclinical evaluation in a porcine coronary artery model.

Waksman R, Zumstein P, Pritsch M, Wittchow E, Haude M, Lapointe-Corriveau C, Leclerc G, Joner M.

EuroIntervention. 2017 Jul 20;13(4):440-449. doi: 10.4244/EIJ-D-16-00915.

3.

Still room for improvement: Preclinical and bench testing of a thin-strut cobalt-chromium bare-metal stent with passive coating.

Wittchow E, Hartwig S.

J Biomed Mater Res B Appl Biomater. 2017 Aug;105(6):1612-1621. doi: 10.1002/jbm.b.33702. Epub 2016 May 5.

PMID:
27149341
4.

Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents.

Koppara T, Cheng Q, Yahagi K, Mori H, Sanchez OD, Feygin J, Wittchow E, Kolodgie FD, Virmani R, Joner M.

Circ Cardiovasc Interv. 2015 Jun;8(6):e002427. doi: 10.1161/CIRCINTERVENTIONS.115.002427.

PMID:
26022535
5.

Pathological aspects of bioresorbable stent implantation.

Sanchez OD, Yahagi K, Byrne RA, Mori H, Zarpak R, Wittchow E, Foin N, Virmani R, Joner M.

EuroIntervention. 2015;11 Suppl V:V159-65. doi: 10.4244/EIJV11SVA39. Review.

6.

Permanent and biodegradable polymer coatings in the absence of antiproliferative drugs in a porcine model of coronary artery stenting.

Koppara T, Wittchow E, Byrne RA, Bayer G, Diener T, Joner M.

EuroIntervention. 2016 Jan 22;11(9):1020-6. doi: 10.4244/EIJY14M10_08.

7.

Inhibition of Orai1-mediated Ca(2+) entry is a key mechanism of the antiproliferative action of sirolimus in human arterial smooth muscle.

König S, Browne S, Doleschal B, Schernthaner M, Poteser M, Mächler H, Wittchow E, Braune M, Muik M, Romanin C, Groschner K.

Am J Physiol Heart Circ Physiol. 2013 Dec 1;305(11):H1646-57. doi: 10.1152/ajpheart.00365.2013. Epub 2013 Sep 20.

8.

Bioresorbable drug-eluting magnesium-alloy scaffold: design and feasibility in a porcine coronary model.

Wittchow E, Adden N, Riedmüller J, Savard C, Waksman R, Braune M.

EuroIntervention. 2013 Apr 22;8(12):1441-50. doi: 10.4244/EIJV8I12A218.

9.

A TRPC3 blocker, ethyl-1-(4-(2,3,3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate (Pyr3), prevents stent-induced arterial remodeling.

Koenig S, Schernthaner M, Maechler H, Kappe CO, Glasnov TN, Hoefler G, Braune M, Wittchow E, Groschner K.

J Pharmacol Exp Ther. 2013 Jan;344(1):33-40. doi: 10.1124/jpet.112.196832. Epub 2012 Sep 25.

PMID:
23010361
10.

Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.

Koppara T, Joner M, Bayer G, Steigerwald K, Diener T, Wittchow E.

Thromb Haemost. 2012 Jun;107(6):1161-71. doi: 10.1160/TH12-01-0043. Epub 2012 Apr 26.

PMID:
22535188
11.

Preclinical evaluation of a novel drug-eluting balloon in an animal model of in-stent stenosis.

Joner M, Radke PW, Byrne RA, Hartwig S, Steigerwald K, Leclerc G, Wittchow E.

J Biomater Appl. 2013 Feb;27(6):717-26. doi: 10.1177/0885328211423784. Epub 2012 Jan 19.

PMID:
22262578
12.

Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients.

Radke PW, Joner M, Joost A, Byrne RA, Hartwig S, Bayer G, Steigerwald K, Wittchow E.

EuroIntervention. 2011 Oct 30;7(6):730-7. doi: 10.4244/EIJV7I6A116.

13.

Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis.

Joner M, Byrne RA, Lapointe JM, Radke PW, Bayer G, Steigerwald K, Wittchow E.

Thromb Haemost. 2011 May;105(5):864-72. doi: 10.1160/TH10-11-0698. Epub 2011 Feb 8.

PMID:
21301785
14.

Efficacy and safety of pimecrolimus-eluting stents in porcine coronary arteries.

Waksman R, Pakala R, Baffour R, Hellinga D, Seabron R, Tio FO, Wittchow E, Tittelbach M, Diener T, Harder C, Virmani R, Jones R.

Cardiovasc Revasc Med. 2007 Oct-Dec;8(4):259-74.

PMID:
18053948
15.

Efficacy and safety of absorbable metallic stents with adjunct intracoronary beta radiation in porcine coronary arteries.

Waksman R, Pakala R, Okabe T, Hellinga D, Chan R, Tio MO, Wittchow E, Hartwig S, Waldmann KH, Harder C.

J Interv Cardiol. 2007 Oct;20(5):367-72.

PMID:
17880333
16.

Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries.

Waksman R, Pakala R, Kuchulakanti PK, Baffour R, Hellinga D, Seabron R, Tio FO, Wittchow E, Hartwig S, Harder C, Rohde R, Heublein B, Andreae A, Waldmann KH, Haverich A.

Catheter Cardiovasc Interv. 2006 Oct;68(4):607-17; discussion 618-9.

PMID:
16969879

Supplemental Content

Loading ...
Support Center